As per the letter enclosed.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Dr Agarwal's Eye Hospital Ltd (AEHL) has approved a Scheme of Amalgamation to merge AEHL into its holding company Dr Agarwal's Health Care Ltd (AHCL) by absorption. Under the scheme, AEHL shareholders (other than AHCL) will receive 23 equity shares of AHCL (₹1 face value) for every 2 equity shares of AEHL (₹10 face value) held. The board also approved a preferential allotment of 1,32,827 equity shares to AHCL at ₹5,270 per share, which would marginally raise AHCL's stake in AEHL from 71.90% to 72.67%. The merger is a related-party transaction between a subsidiary and its parent (AHCL), with AHCL's consolidated turnover at ₹1,711 crore against AEHL's standalone turnover of ₹397.15 crore (FY25). The scheme requires NCLT, SEBI, stock exchange, and shareholder approvals. The 31st AGM is scheduled for September 24, 2025.
Public shareholders of AEHL will receive AHCL shares in exchange for their AEHL shares at the stated swap ratio, effectively transferring their listing to AHCL (already listed since Feb 2025). Post-merger, AEHL will cease to exist as a separate entity. The deal is expected to be EPS-accretive from year one per the company, but investors should watch the NCLT approval timeline and the final swap ratio fairness.